Moderna, Inc. (LON:0A45)

London flag London · Delayed Price · Currency is GBP · Price in USD
27.17
+0.76 (2.87%)
At close: Aug 22, 2025
2.87%
Market Cap7.79B
Revenue (ttm)2.25B
Net Income (ttm)-2.12B
Shares Outn/a
EPS (ttm)-5.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,462
Average Volume69,156
Open26.20
Previous Close26.41
Day's Range26.16 - 27.79
52-Week Range23.16 - 88.48
Beta1.83
RSI44.24
Earnings DateJul 31, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 5,800
Stock Exchange London Stock Exchange
Ticker Symbol 0A45
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.